The emergence of cellular immunotherapy treatments isintroducing more efficient strategies to combat cancer as well as autoimmuneand infectious diseases. However, the cellular manufacturing proceduresassociated with these therapies remain costly and time-consuming, thus limitingtheir applicability. Recently, lymph-node-inspired PEG−heparin hydrogels havebeen demonstrated to improve primary human T cell culture at the laboratoryscale. To go one step further in their clinical applicability, we assessed theirscalability, which was successfully achieved by 3D printing. Thus, we were ableto improve primary human T cell infiltration in the biohybrid PEG−heparinhydrogels, as well as increase nutrient, waste, and gas transport, resulting inhigher primary human T cell proliferation rates while maintaining thephenotype. Thus, we moved one step further toward meeting the requirementsneeded to improve the manufacture of the cellular products used in cellularimmunotherapies.